• Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

  NCT02511847

  Unknown statusInterventionalPhase 2Updated Apr 15, 2016
• Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment

  NCT02274012

  WithdrawnInterventionalPhase 2Updated Mar 14, 2017
• Afatinib in NSCLC With HER2 Mutation

  NCT02597946

  CompletedInterventionalPhase 2Updated Feb 19, 2025
• Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

  NCT02044380

  CompletedInterventionalPhase 3Updated Mar 31, 2017
• Afatinib in NSCLC With HER2 Mutation

  NCT02369484

  CompletedInterventionalPhase 2Updated Aug 26, 2026
• Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

  NCT01953913

  CompletedInterventionalPhase 3Updated Aug 12, 2019

ClinicalTrials.gov ID

NCT03810872

Lead Sponsor

Universitair Ziekenhuis BrusselOTHER

Overall Status

Unknown status

Study Type

Interventional

Phase

Phase 2

Enrollment

87Estimated

Last Update Posted

Jan 22, 2019Actual

Start Date

Jun 21, 2017Actual

Primary Completion Date

Dec 2020Estimated

Completion Date

Dec 2022Estimated

Official Title

An Open Explorative Phase II, Open Label Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Brief Summary

Objective(s):To investigate the efficacy and safety of afatinib in EGFR, HER 2 and HER3 mutated cancers, regardless of cancer type, excluding EGFR mutated non-small cell lung cancer.

Methodology:Open label, genomic driven trial (basket trial)

No. of patients total entered:Optimal Simon two stage design for the three genetic driven cohorts: 10 patients will be enrolled per cancer type in the first stage and an additional 19 in the second stage (maximum total 87 patients)

Indication : cancers harbouring an EGFR mutation(excluding non-squamous non- small cell lung cancer, a registered indication), a HER2 mutation or a HER3 mutation

Test product(s) : Afatinib At progression paclitaxel will be added for those patients that have no contra-indications

dose: Starting dose of afatinib at 40 mg/day. Dose increase to 50 mg in the absence of adverse events. Stepwise dose reduction to 30,20, 10 mg/day according to drug-related adverse events.

At progression, addition of paclitaxel 80 mg/m2 weekly 3w/4 to afatinib 40 mg/day .

mode of admin. : Oral for afatinib Intravenous for paclitaxel

Duration of treatment: Continuous treatment until progression or unacceptable adverse events or withdrawal of consent.

At disease progression, add paclitaxel until progression or unacceptable adverse event or withdrawal of consent if no contra-indications.

Criteria for efficacy: Primary Endpoint:

• Response rate (CR+ PR) via RECIST v1.1

Secondary Endpoints:

• Disease control rate (CR+PR+SD)
• Progression free survival
• Overall survival
• To correlate tumor response with findings on tumor biopsies
• To investigate resistance mechanisms
• response rate (CR+ PR) determined by RECIST and progression free survival on the combination therapy of afatinib and paclitaxel

Criteria for safety: Incidence and intensity of adverse events according CTCAE v4.0

• Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

• Afatinib
• Paclitaxel

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Women and men with locally advanced or metastatic cancers harboring either an activating EGFR mutation or a HER2 mutation or a HER3 mutation
• Failure of at least one line of standard systemic therapy
• No eligibility for other open genomic driven phase I, II or III trial available for these tumor genotypes
• ECOG performance status ≤2
• Patient with a life expectancy >3 months
• Patients able to provide written informed consent prior to enrollment into the clinical trial.
• Adequate organ function

Exclusion Criteria:

• Non squamous non-small cell lung cancer harbouring an EGFR mutation (registered indication)
• Chemotherapy, biological therapy or investigational agents within four weeks prior to the start of study treatment
• Known hypersensitivity to afatinib or the excipients of any of the trial drugs
• Prior treatment with afatinib

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Universitair Ziekenhuis BrusselOTHER

ann.clue@uzgent.be